Business Wire

flatexDEGIRO Reaches Three Million Customers

Share

Following continued growth over the last years, the total number of customers at flatexDEGIRO now exceeds the three million mark. The pan-European online broker has more than tripled its customer base since 2020 and won an additional 400,000 new customers over the last 12 months alone.

“Over the past few years, we have experienced remarkable growth in our customer base and I would like to thank our customers for their trust and support," said Oliver Behrens, CEO of flatexDEGIRO AG. He confirmed the upcoming launch of crypto trading which will further expand the online broker’s product range. “We will have a very attractive offering for our customers to trade crypto currencies on our platforms,” Behrens added.

With close to 900,000 customers, flatexDEGIRO has its largest customer base in the Netherlands, the home market of its DEGIRO brand. Germany, where flatex started its price attractive flat fee execution model in 2006, is home to over 500,000 customers. Austria and Spain, with around 300,000 customers each, as well as other larger growth markets - such as France, Italy, Portugal and Switzerland - are showing some of the highest growth rates year-to-date.

Customer assets on the flatexDEGIRO platforms have constantly risen over recent years to a record-level today of around 66 billion Euro, with cash-inflows from customers amounting to over 500 million Euro a month on average.

About flatexDEGIRO AG

flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates one of the leading and fastest growing online brokerage platforms in Europe. Based on modern, in-house state-of-the-art technology, customers of the flatex and DEGIRO brands are offered a wide range of independent products with execution on top TIER 1 exchanges. The technological edge, high efficiency and strong economies of scale enable flatexDEGIRO to continuously improve its service offering for clients and set leading standards in terms of product, price and platform quality.

With over 3 million customer accounts and around 60 million securities transactions processed in 2023, flatexDEGIRO is one of the largest retail online brokers in Europe. In times of bank consolidation, low real interest rates and digitalization, flatexDEGIRO is ideally positioned for further growth.

Further information can be found at https://www.flatexdegiro.com/en

Language:

English

Company:

flatexDEGIRO AG

Omniturm, Große Gallusstraße 16-18

60312 Frankfurt / Main

Germany

Phone:

+49 (0) 69 450001 0

E-mail:

ir@flatexdegiro.com

Internet:

www.flatexdegiro.com

ISIN:

DE000FTG1111

WKN:

FTG111

Indices:

SDAX

Listed:

Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich, Stuttgart, Tradegate Exchange

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113284955/en/

Contacts

Achim Schreck Phone +49 (0) 69 450001 1700
Head of IR & Corporate Communications achim.schreck@flatexDEGIRO.com

Laura Hecker Phone +49 (0) 160 3064 404
Director Investor Relations laura.hecker@flatexdegiro.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Group Holdings Inc. Reports Third Quarter 2024 Financial Results13.11.2024 22:59:00 CET | Press Release

SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Total revenues for the three months ended September 30, 2024 were $53 million, representing an increase of 12% from $47 million in the same quarter of 2023. Total revenues for the nine months ended September 30, 2024 was $160 million, representing an increase of 23% from $131 million in the same period of 2023. Income from operations for the three months ended September 30, 2024 was $13 million, representing a decrease by 31% from the same quarter in 2023. This result was impacted by $12.8 million of stock-based compensation expense related to the Company’s listing process. Income from operations for the nine months ended September 30, 2024 was $65.5 million, representing an increase o

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services13.11.2024 18:00:00 CET | Press Release

Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research. For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Québec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This

Medidata Secures Highest Leadership Position in Everest Group’s First Life Sciences Clinical Trial Management System Products PEAK Matrix ® Assessment13.11.2024 15:30:00 CET | Press Release

Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, has been recognized as a leader in Everest Group's first-ever Life Sciences Clinical Trial Management System Products PEAK Matrix® Assessment 2024. The report assessed 13 providers based on the market impact of their products and their ability to deliver successful, high-quality offerings. Medidata Rave CTMS leads the industry by providing seamless, real-time patient data outputs that transform enrollment tracking and enable faster, data-driven decisions. Offering instant visibility for study teams, Rave CTMS streamlines collaboration, eliminates manual data entry, and accelerates trial timelines with exceptional accuracy. “We are honored to be recognized as the highest leader in CTMS by Everest Group,” said Tom Doyle, chief technology officer, Medidata. “This accolade underscores our unwavering commitment to transforming research and reaffirms our strategy to deliver

China Moutai Showcases Ecology Promotion Practices at the China Pavilion During COP2913.11.2024 15:05:00 CET | Press Release

At a side event titled "Ecological Civilization and Beautiful China Practices" during the 2024 UN Climate Change Conference (COP29) in Baku, Azerbaijan, China Moutai showcased its commitment to ecological sustainability and called for greater attention to climate change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113718721/en/ Li Wang, General Manager of China Moutai Group, presented at the side event in Baku. (Photo: Business Wire) Li Wang, General Manager of China Moutai Group, emphasized that Chinese modernization is rooted in achieving harmony between humanity and nature. She said that as a representative of China’s liquor industry, Moutai has embraced the principle that "lucid waters and lush mountains are invaluable assets." This philosophy underscores the company’s approach to modernization, which prioritizes environmental stewardship. Wang highlighted Moutai Group’s dedication to leveraging regional ecological

Andersen Global Adds M&A and Investment Banking Capabilities to Platform in South Africa13.11.2024 15:00:00 CET | Press Release

Andersen Global continues to build its multidisciplinary platform in South Africa through a Collaboration Agreement with Merchantec Capital, an M&A and investment banking firm based in Johannesburg. Operating for over two decades, Merchantec Capital offers a diverse range of services, including mergers and acquisitions advisory, valuations, equity and debt capital raising services, corporate governance, JSE equity and debt sponsor services, research, and wealth management. The firm works with public companies, large corporations, privately-owned businesses, management teams, and private equity firms, providing strategic solutions that meet both local and international business needs. “Providing objective, one-stop solutions for clients has been a key objective and driving force behind our growth to date,” shared Executive Director Marcel Goncalves. “This collaboration with Andersen Global enables us to continue to serve clients objectively and expands our reach to assist clients with c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye